Table 2.
Clinical trials of multidisciplinary treatment strategy for locally advanced resectable esophageal adenocarcinoma
| Study name (year) | Histologic subtypea | Treatment armsb | Main resultsc | P value |
|---|---|---|---|---|
| OEO2 (2002) | SCC, AC |
Surgery alone CF + surgery |
5-year OS 17% 5-year OS 23% |
0.03 |
| MAGIC (2006) | Esophagogastric AC |
Surgery alone ECF + surgery + ECF |
5-year OS 23% 5-year OS 36% |
0.009 |
|
FNCLCC-FFCD 9703 (2011) |
Esophagogastric AC |
Surgery alone CF + surgery (+CF) |
5-year OS 24% 5-year OS 38% |
0.02 |
| CROSS (2012) | SCC, AC |
Surgery alone CRT + surgery |
Median OS 24.0 M Median OS 49.4 M |
0.003 |
| FLOT4 (2017) | Esophagogastric AC |
ECF or ECX + surgery + ECF or ECX FLOT + surgery + FLOT |
Median OS 35 M Median OS 50 M |
0.012 |
| Neo-AEGIS (ongoing) | Esophagogastric AC |
CRT + surgery (CROSS) Peri CT (ECF, ECX, EOF, EOX) |
– | – |
| ESOPEC (ongoing) | Esophagogastric AC |
CRT + surgery (CROSS) FLOT + surgery + FLOT |
– | – |
| TOPGEAR (ongoing) | Esophagogastric AC |
Peri CT (ECF/ECX) Peri CRT (ECF + CRT + surgery + ECF/ECX) |
– | – |
aSCC squamous cell carcinoma, AC adenocarcinoma
bCF cisplatin + 5-fluorouracil, ECF epirubicin + cisplatin + 5-fluorouracil, CRT chemoradiotherapy, ECX epirubicin + cisplatin + xeloda, FLOT 5-fluorouracil + leucovorin + oxaliplatin + taxotere, DCF docetaxel + cisplatin + 5-fluorouracil, Peri CT perioperative chemotherapy
cDFS disease-free survival, OS overall survival